BRPI0413449A - compostos de quinoxalina - Google Patents

compostos de quinoxalina

Info

Publication number
BRPI0413449A
BRPI0413449A BRPI0413449-4A BRPI0413449A BRPI0413449A BR PI0413449 A BRPI0413449 A BR PI0413449A BR PI0413449 A BRPI0413449 A BR PI0413449A BR PI0413449 A BRPI0413449 A BR PI0413449A
Authority
BR
Brazil
Prior art keywords
quinoxaline compounds
cck2
quinoxaline
compounds
amidophenyl
Prior art date
Application number
BRPI0413449-4A
Other languages
English (en)
Inventor
Brett D Allison
Michael D Hack
Victor K Phuong
Michael H Rabinowitz
Mark D Rosen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0413449A publication Critical patent/BRPI0413449A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

"COMPOSTOS DE QUINOXALINA". Certos compostos de amidofenil-sulfonilamino-quinoxalina são moduladores de CCK2 úteis no tratamento de doenças mediadas por CCK2.
BRPI0413449-4A 2003-08-08 2004-08-04 compostos de quinoxalina BRPI0413449A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49407403P 2003-08-08 2003-08-08
PCT/US2004/025153 WO2005016896A1 (en) 2003-08-08 2004-08-04 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators

Publications (1)

Publication Number Publication Date
BRPI0413449A true BRPI0413449A (pt) 2006-10-17

Family

ID=34193199

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413449-4A BRPI0413449A (pt) 2003-08-08 2004-08-04 compostos de quinoxalina

Country Status (33)

Country Link
US (3) US7288651B2 (pt)
EP (2) EP1651621B1 (pt)
JP (2) JP2007501842A (pt)
KR (1) KR20060060007A (pt)
CN (2) CN1863782A (pt)
AR (1) AR045930A1 (pt)
AT (2) ATE403650T1 (pt)
AU (2) AU2004265311A1 (pt)
BR (1) BRPI0413449A (pt)
CA (2) CA2534885C (pt)
CR (1) CR8229A (pt)
CY (1) CY1106486T1 (pt)
DE (2) DE602004015614D1 (pt)
DK (2) DK1651621T3 (pt)
EA (1) EA200600203A1 (pt)
EC (1) ECSP066355A (pt)
ES (2) ES2310294T3 (pt)
HR (1) HRP20080559T3 (pt)
IL (1) IL173591A0 (pt)
IS (1) IS8280A (pt)
LT (1) LT5410B (pt)
LV (1) LV13453B (pt)
MX (2) MXPA06001550A (pt)
NO (1) NO20061122L (pt)
NZ (1) NZ545030A (pt)
PL (2) PL1651621T3 (pt)
PT (2) PT1651622E (pt)
SG (1) SG131114A1 (pt)
SI (2) SI1651621T1 (pt)
TW (1) TW200521120A (pt)
UA (1) UA84025C2 (pt)
WO (2) WO2005016896A1 (pt)
ZA (1) ZA200601946B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1651621T3 (pl) * 2003-08-08 2009-01-30 Janssen Pharmaceutica Nv Związki 2-(chinoksalin-5-ylosulfonyloamino)benzamidowe jako modulatory CCK2
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
US7947833B2 (en) * 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
CN101061116A (zh) 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) * 2007-01-12 2013-11-26 The Board Of Trustees Of The Leland Stanford Junior University Preparation of azide-modified carbon surfaces for coupling to various species
JP5497429B2 (ja) * 2007-03-07 2014-05-21 武田薬品工業株式会社 ベンゾオキサゼピン誘導体およびその用途
WO2008124518A1 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131245A3 (en) * 2008-06-02 2012-08-01 ASML Netherlands BV Lithographic apparatus and its focus determination method
WO2009154754A2 (en) * 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
WO2010118208A1 (en) * 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
JP5815029B2 (ja) 2010-07-09 2015-11-17 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネル遮断薬としてのテトラゾール化合物
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
BR112013018771A2 (pt) 2011-01-26 2019-09-17 Zafgen Inc compostos de tetrazol e métodos para fazer e usar os mesmos
EP2705030B1 (en) 2011-05-06 2016-07-27 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
CN104169268A (zh) 2012-01-18 2014-11-26 扎夫根股份有限公司 三环砜化合物及其制备和使用方法
PL3345899T3 (pl) 2012-03-01 2020-07-27 Allergan, Inc. Pochodne benzofurano-2-sulfonoamidu jako modulatory receptorów chemokin
US9561209B2 (en) 2012-11-05 2017-02-07 Zafgen, Inc. Methods of treating liver diseases
BR112015010223A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
JP2015536981A (ja) 2012-11-05 2015-12-24 ザフゲン，インコーポレイテッド 三環式化合物ならびにその製造および使用方法
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) * 2013-10-24 2016-05-18 江苏鼎龙科技有限公司 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
BR112016011727A2 (pt) 2013-11-22 2017-08-08 CL BioSciences LLC Antagonistas de gastrina para o tratamento e prevenção de osteoporose
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN106565509A (zh) * 2016-11-03 2017-04-19 江苏鼎龙科技有限公司 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko) * 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108218806B (zh) * 2018-04-02 2019-03-01 上海馨远医药科技有限公司 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200420D0 (en) 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
AU682051B2 (en) * 1993-08-10 1997-09-18 James Black Foundation Limited Gastrin and CCK receptor ligands
CN1130351C (zh) 1996-12-10 2003-12-10 泽里新药工业株式会社 1,5－苯并二氮杂䓬衍生物
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
ITTO20020674A1 (it) * 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) * 2002-11-14 2005-09-13 Bristol-Myers Squibb Company N-cycloalkylglycines as HIV protease inhibitors
PL1651621T3 (pl) * 2003-08-08 2009-01-30 Janssen Pharmaceutica Nv Związki 2-(chinoksalin-5-ylosulfonyloamino)benzamidowe jako modulatory CCK2
CN101061116A (zh) * 2004-09-24 2007-10-24 詹森药业有限公司 磺酰胺化合物

Also Published As

Publication number Publication date
CA2534885C (en) 2013-06-04
ES2310294T3 (es) 2009-01-01
AR045930A1 (es) 2005-11-16
SG131114A1 (en) 2007-04-26
ES2281834T3 (es) 2007-10-01
NZ545030A (en) 2009-08-28
AU2004265311A1 (en) 2005-02-24
EP1651621B1 (en) 2008-08-06
JP2007501841A (ja) 2007-02-01
IS8280A (is) 2006-01-31
CN1863781A (zh) 2006-11-15
CN1863782A (zh) 2006-11-15
SI1651621T1 (sl) 2008-12-31
US7563895B2 (en) 2009-07-21
US20080076918A1 (en) 2008-03-27
WO2005016897A1 (en) 2005-02-24
DK1651622T3 (da) 2007-05-07
MXPA06001482A (es) 2006-09-04
PT1651622E (pt) 2007-04-30
JP2007501842A (ja) 2007-02-01
EP1651622B1 (en) 2007-02-07
ATE353322T1 (de) 2007-02-15
DE602004004663D1 (de) 2007-03-22
AU2004265312A1 (en) 2005-02-24
NO20061122L (no) 2006-05-04
DE602004004663T2 (de) 2007-11-22
LT2006017A (en) 2006-11-27
CR8229A (es) 2008-09-10
CA2534885A1 (en) 2005-02-24
US20050043310A1 (en) 2005-02-24
JP4818110B2 (ja) 2011-11-16
TW200521120A (en) 2005-07-01
DE602004015614D1 (de) 2008-09-18
LV13453B (en) 2007-02-20
US7288651B2 (en) 2007-10-30
SI1651622T1 (sl) 2007-06-30
DK1651621T3 (da) 2008-11-10
US20050038032A1 (en) 2005-02-17
EA200600203A1 (ru) 2006-08-25
PL1651621T3 (pl) 2009-01-30
PT1651621E (pt) 2008-09-30
ZA200601946B (en) 2007-05-30
AU2004265312B2 (en) 2010-05-20
EP1651622A1 (en) 2006-05-03
LT5410B (lt) 2007-03-26
CY1106486T1 (el) 2012-01-25
US7304051B2 (en) 2007-12-04
MXPA06001550A (es) 2006-09-04
IL173591A0 (en) 2006-07-05
HRP20080559T3 (en) 2009-01-31
WO2005016896A1 (en) 2005-02-24
KR20060060007A (ko) 2006-06-02
EP1651621A1 (en) 2006-05-03
CA2534887A1 (en) 2005-02-24
ECSP066355A (es) 2006-08-30
UA84025C2 (en) 2008-09-10
PL1651622T3 (pl) 2007-07-31
ATE403650T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
BRPI0413449A (pt) compostos de quinoxalina
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TW200509892A (en) Novel aminobenzophenone compounds
DE602004028359D1 (de) Reinigung von biologisch produziertem 1,3-propandiol
ATE461217T1 (de) Glp-1-verbindungen
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
EP1432714A4 (en) CHEMICAL COMPOUNDS
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
SE0301653D0 (sv) Novel compounds
SE9802729D0 (sv) Novel Compounds
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
CR8009A (es) Compuestos benzo[1,2,5] tiadiazoles
CU23088A3 (es) Compuestos de tetra-hidropiridina.
DE50310579D1 (de) Furancarboxamide
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
DE50311756D1 (de) Mikrobizide oxathiincarboxamide
BRPI0415355A (pt) triarilimidazóis
NO20053562L (no) Nye aminobenzofenonforbindelser
BR0316544A (pt) Compostos calcilìticos
NO20005548L (no) Mykobakterieinhibitorer
PT1244614E (pt) Inibidores de triptase
MY140194A (en) Novel fusidic acid derivatives
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.